Navigation Links
Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease
Date:11/12/2008

MIAMI, Nov. 12 /PRNewswire/ -- The Miami Jewish Home and Hospital, Berma Research Group, and Segal Institute for Clinical Research today announced that they are actively enrolling patients in the CONNECTION study, a Phase 3 clinical trial that is evaluating the safety and efficacy of the investigational drug Dimebon as a treatment for mild-to-moderate Alzheimer's disease.

According to new estimates from the Alzheimer's Association, more than 5 million people in the United States are living with Alzheimer's disease, a progressive, debilitating and deadly disease that destroys brain cells and affects areas of the brain involved in memory, cognition, judgment, language and behavior. As the baby boomer population ages, the incidence of Alzheimer's disease is expected to increase dramatically. Currently available therapies for Alzheimer's treat the symptoms with modest effect, and there is no evidence that these medications alter the course of the underlying disease process.

"New therapies are urgently needed to more effectively treat the symptoms of Alzheimer's disease," said Dr. Marc Agronin, director of mental health services at the Miami Jewish Home and Hospital and associate professor of psychiatry at the University of Miami Miller School of Medicine. "Results from a previous study of Dimebon in Alzheimer's disease were encouraging, and we look forward to further assessing Dimebon's promise in the fight against Alzheimer's disease in the CONNECTION study. We encourage local patients and caregivers to learn more about this trial."

About Dimebon

Dimebon is an investigational therapy in clinical development for the treatment of Alzheimer's disease. It targets Alzheimer's disease differently than currently available therapies. Mitochondria (a cell's primary source of energy) are the target of Dimebon's mechanism of action.

Medivation, Inc., the company developing Dimebon and sponsoring the CONNECTION study, previously announced efficacy and safety results from the first pivotal trial showing that Dimebon improved the clinical course of Alzheimer's disease. In that study, patients treated with Dimebon showed significant improvement over patients treated with placebo (sugar pill) in each of the five most important aspects of Alzheimer's: memory, thinking, behavior, activities of daily living (such as eating and hygiene) and overall function. These improvements were seen after as little as 12 weeks of treatment with Dimebon and were maintained over a full year of treatment. Dimebon was well tolerated throughout the one-year treatment period.

About the CONNECTION Study

The CONNECTION study will enroll 525 patients in the United States -- as well as sites in Europe and South America -- to test the effects of Dimebon in patients with mild-to-moderate Alzheimer's disease. The study will evaluate the impact of Dimebon on cognition (thinking and awareness), memory, daily functioning, behavior and the ability to care for oneself.

Patients age 50 and older who are not taking any other Alzheimer's prescription medications may be eligible for the six-month study. Patients will randomly be chosen to receive either Dimebon or placebo. After six months of treatment, all patients -- including those receiving placebo -- will be offered the opportunity to receive Dimebon in an extension trial.

For more information on eligibility and enrollment, patients and caregivers can contact:

Miami Jewish Home & Hospital: 305-514-8503, http://www.mjhha.org

Berma Research Group: 305-702-9453, http://www.bermaresearch.com

Segal Institute for Clinical Research: 1-877-SEGAL-88,

http://www.segaltrials.com

CONNECTION study: 1-877-888-6386, http://www.connectionstudy.com


'/>"/>
SOURCE Miami Jewish Home & Hospital; Berma Research Group; SegalInstitute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
2. Miami Plastic Surgeon Offers Hope to Acne Scarred Patients
3. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami
4. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
7. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
8. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
9. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
10. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
11. Alzheimers Association Grant Furthers Successful Research at UMass Lowell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Walgreens has committed to provide drug disposal kiosks ... D.C. as part of a program to combat ... advocacy organization As You Sow. Conrad MacKerron , ... on to unneeded drugs because they lack easily accessible collection ... --> Conrad MacKerron , Senior Vice President at As ...
(Date:2/11/2016)... 11, 2016   Health 2.0 , the premiere ... technologies, announced today " 10 Year Global Retrospective ", ... over the past ten years.   ... Health 2.0 has served as the preeminent thought-leader in ... thousands of technologies, companies, innovators, and patient-activists through an ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent ... cosmetic procedures. Along with performing procedures, the magazine also highlights that Dr. Sadati ... procedures. One of the most common procedures he performs is his natural facelift. ...
(Date:2/11/2016)... Chicago, IL (PRWEB) , ... February 11, 2016 ... ... dedicated to the healthcare industry, ranked among the top five firms in the ... Services and HIT Implementation Support and Staffing. KLAS is a research and insights ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for throwing curves. It’s ... older, who gather once a year to play softball to raise money through ... the more than 50 players who competed in this year’s softball tournament share a ...
(Date:2/11/2016)... Laredo, TX (PRWEB) , ... February 11, 2016 ... ... and surrounding communities with their ongoing community involvement program, introduces a new charity ... with hospitalized children, donations are now being accepted at https://donate.rmhc.org/ . , ...
Breaking Medicine News(10 mins):